Cutting Through Complexity: PCI's Integrated Model For Faster PFS Development

This article explores the rapid rise of prefilled syringes (PFS) as a preferred format for injectable drug delivery and how an integrated, end-to-end development model can accelerate both clinical and commercial timelines. Dawn Manley highlights that growing adoption is fueled by patient-centric design, simplified administration, improved dosing accuracy, and the expansion of biologics and chronic disease therapies.

To meet this demand, a fully connected global approach — spanning sterile fill-finish, device assembly, testing, packaging, and supply chain — helps minimize handoffs and streamline time to market. Backed by investments in advanced filling technologies, scalable PFS capacity, analytical and functional testing, and flexible assembly platforms, this model supports programs from early development through global launch. The article also underscores the importance of early device and packaging strategy, ready-to-use tooling solutions that reduce lead times, and ongoing global expansion to ensure capacity for next-generation injectable and combination products.